Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321085 | 0.88 | KDM4E (0.69) | DRD2SIGMAR1KDM4EGAASLC6A2 | |
| SCHEMBL14852368 | 0.86 | KDM4E (0.72) | DRD2SIGMAR1KDM4EGAASLC6A2 | |
| SCHEMBL578273 | 0.85 | GAA (0.67) | DRD2SIGMAR1KDM4EGAASLC6A2 | |
| SCHEMBL13079491 | 0.83 | KDM4E (0.78) | DRD2SIGMAR1KDM4EGAADRD4 | |
| SCHEMBL81904 | 0.83 | DRD2 (0.70) | DRD2SIGMAR1KDM4EGAAMAPT | |
| SCHEMBL374548 | 0.81 | KDM4E (0.73) | DRD2SIGMAR1KDM4EGAAMAPT | |
| SCHEMBL5185973 | 0.81 | CYP2D6 (0.54) | DRD2SIGMAR1KDM4EGAASLC6A2 | |
| SCHEMBL31744852 | 0.81 | CYP2D6 (0.60) | DRD2SLC6A2SLC6A4DRD4MAPT | |
| SCHEMBL5915112 | 0.81 | DRD2 (0.68) | DRD2SIGMAR1KDM4EGAASLC6A2 | |
| SCHEMBL26508401 | 0.81 | DRD2 (0.68) | DRD2SIGMAR1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2013051672-A1 | MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-7622056-B2 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-11-24 | — | — | US | disclosed |
| US-7622056-B2 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-11-24 | — | — | US | disclosed |
| US-7622056-B2 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-11-24 | — | — | US | disclosed |
| US-20080135803-A1 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE DAILY POLYMER CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080135803-A1 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE DAILY POLYMER CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080135803-A1 | High dielectric anisotropy liquid crystal compound and composition containing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE DAILY POLYMER CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20050256308-A1 | Spiro compounds, medicinal compositions containing the same and intermediates of the compounds | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1559707-A1 | SPIRO COMPOUNDS, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256308-A1 | Spiro compounds, medicinal compositions containing the same and intermediates of the compounds | ESRRA, ESR1, BRCA1 | DRD2 1789/4885SIGMAR1 222/4885KDM4E 3394/4885 |
| US-20080135803-A1 | High dielectric anisotropy liquid crystal compound and composition containing the same | KIF23, PIEZO1, KIFC1 | DRD2 1075/4885SIGMAR1 3790/4885KDM4E 621/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | DRD2 4843/4885SIGMAR1 2751/4885KDM4E 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.